Dr Hugh Calkins, Prof Riyaz Kaba, Prof Carlo de Asmundis, Prof Claudio Tondo and Dr Manuela Cirredu discuss the endocardial approach to managing arrhythmias and which patients may benefit💡 Discover bite-sized chapters from this on-demand symposium: Welcome and introduction 🔗 https://ow.ly/OVEZ50RFAx5 The hybrid approach to the management of arrhythmias – Which patients may benefit? 🔗 https://ow.ly/7RYk50RFAx7 Has PFA changed the approach to patient selection for hybrid ablation? 🔗 https://ow.ly/q2RQ50RFAx9 Review of atrial fibrillation guidelines – What they do and don’t say about hybrid ablation 🔗 https://ow.ly/MWkJ50RFAx6 Discussion – Current and future roles of hybrid ablation 🔗 https://ow.ly/Hjz250RFAx8 This programme is supported by an unrestricted educational grant from AtriCure, Inc.
Radcliffe Cardiology’s Post
More Relevant Posts
-
My talk today in ISRS in New York about long term radiological and endocrinological outcomes following SRS for residual/recurrent NFPA It is durable, safe Please consider SRS in NFPA , it can control tumor with low risk of endocrinopathy up to 10-15 years For further, review our paper published in JNS https://lnkd.in/egd997y4
-
-
Today, at the International Symposium of Amyloidosis, we shared positive results of five new analyses of clinical endpoint events from our Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM. Learn more about the insights and emerging real-world evidence in ATTR: https://bit.ly/3KiKqfk
-
-
Today, we celebrate #WorldHealthDay, and the efforts of the CLINSPECT-M consortium to integrate mass spectrometry-based #proteomics into systems medicine by developing of standardized start-to-finish, fit-for-purpose workflows for clinical specimens. Testing different #samplepreparation and MS protocols on two clinically relevant sample matrices (plasma and cerebrospinal fluid), the six study partners conducted two studies, implementing the most promising protocols from the first round into the second. It was a great example of how the expert-driven exchange of knowledge and best practices can result in direct practical improvements that benefit the scientific community and, ultimately, patients. And it was especially gratifying to see our iST-BCT and SP3-iST kits do so well! Read more about the study and its results: https://ow.ly/wfVw50R3o5k
-
-
I'm really excited about this webinar. Not only is it on an important topic scientifically and ethically, but there's a lot of hype and bombastic claims about brain-machine interfaces that need to be tempered. Sign up below! #neurology #bioengineering
The global landscape for clinical trials on implanted brain-computer interfaces is dynamic, changing, and the focus of intense interest. However, information on clinical trial progress of implanted brain-computer interfaces remains scarce. Join our webinar with field leaders Jose L Contreras-Vidal, Ph.D. and Mariska van Steensel to talk about the state of clinical trials of implantable brain-computer interfaces. We invite you to hear their insights, ask questions, and contribute to this timely discussion. Register here: https://lnkd.in/eRQSR_uk
-
-
One more day to submit your short talk and poster abstracts #EASD2024!
Abstract deadline May 30th! We seek submissions for short talks and poster session at our one-day meeting during the industry session at #EASD2024. Abstracts selected for short talks will receive a travel award. Topics can include how alpha and delta cell dysfunction leads to hypoglycemia and efforts to therapeutically restore the body’s ability to reverse it. More information about the symposium and abstract submission at https://bit.ly/3VdW1CX
-
-
Dr. Odayme Quesada, Medical Director of the Women's Heart Center at The Christ Hospital, discusses how the CorMicA trial "has changed the way we look at diagnosis for ANOCA and INOCA patients". In the CorMicA trial, researchers demonstrated that "angina improved in patients who had interventions based on their diagnosis", suggesting the need for more stratified, personalized care in patients experiencing angina but without obstructed coronary arteries, many of whom have coronary microvascular dysfunction (CMD). To hear other insights just like this, watch “Coronary Microvascular Dysfunction and Its Hidden Role in Persistent Angina”, now online and on-demand at European Medical Journal: https://lnkd.in/g8iTQh-g
-
Join us at #UEGWeek where Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will present data on target achievement in patients with moderate to severe ulcerative colitis participating in the VERDICT study, a trial focused on evaluating different algorithms of achieving treatment target in ulcerative colitis. Stop by booth #57 to learn more about our innovative research! #Alimentiv #IBD #ClinicalResearch
-
-
As healthcare marketers, understanding the evolving landscape of R&D in chronic diseases is paramount. Immunic, Inc. is set to host a Multiple Sclerosis R&D Day on September 10, featuring insights from industry leaders on innovative therapies like vidofludimus calcium. With participation in key scientific conferences throughout September, this is an opportunity to grasp emerging trends and strategic directions in MS treatment. Mark your calendars! #HealthcareMarketing #MSResearch #Immunic
-
Kicking off from an excellent collaboration with Prof. David Hunter and Xiaoqian Liu, we're excited to share our latest publication comparing #placebo responses in internet-based versus onsite randomized controlled trials (RCTs) for hand osteoarthritis. 🔬 The study revealed no significant differences in placebo responses between the two study settings. Additionally, with the support of Placebell's digital solution, we found no differences in placebo response predictors, underscoring the reliability and efficacy of internet-based RCTs. This breakthrough paves the way for remote trials as a viable alternative and has the potential to enhance patient diversity and inclusion in clinical research. Learn more about the potential of internet RCTs in medical research → https://bit.ly/4bd0g7q
-
-
“The scientific status and future of the therapies in Anthroposophic Medicine” Where do we stand? What are the barriers and opportunities for the further development and implementation of the therapies in anthroposophic medicine (AM) and for AM therapy research? How do we connect to current developments? What must and can we do in the next 10 years? An AM research congress on evidence, relevant developments in AM, conventional medicine and Traditional, Complementary & Integrative Healthcare (TCIH), research communities and research agendas development for the future. Programm und Anmeldung: https://lnkd.in/eEqCn9Qr
